Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of subcutaneous mannan-conjugated polymerised grass pollen allergoid in adults with grass pollen allergic rhinitis or rhinoconjunctivitis
2025-524580-21-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- May 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of mannan-conjugated polymerised Phleum pratense + Dactylis glomerata allergoid, sponsored by Inmunotek. Planned start May 2026; status: authorised.
02
Drugs
mannan-conjugated polymerised Phleum pratense + Dactylis glomerata allergoid
Beyond the preview
Go deeper on 2025-524580-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524580-21-00.